LPTX LEAP THERAPEUTICS INC US FDA Inspections 8-K Filing 2023 - Other Events Leap Therapeutics announced completion of enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients.Get access to all SEC 8-K filings of the LEAP THERAPEUTICS INC